Sarah Debaveye

Sarah Debaveye

Auto-generated profile, based on publicly available information

Sarah Debaveye

KU Leuven

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Nature
Verified
Journal Article
Closed access
PDF file
LSLorena Sanchez-Felipe
Lorena Sanchez-Felipe
TVThomas Vercruysse
Thomas Vercruysse
SSSapna Sharma
Sapna Sharma
JMJi Ma
Ji Ma
VLViktor Lemmens
Viktor Lemmens
KDKai Dallmeier
Kai Dallmeier

18 January 2021 in RNA Biology
Verified
Journal Article
Open access
SJSander Jansen
Sander Jansen
ESEnisa Smlatic
Enisa Smlatic
DCDaniëlle Copmans
Daniëlle Copmans
SDSarah Debaveye
Sarah Debaveye
FTFrédéric Tangy
Frédéric Tangy
KDKai Dallmeier
Kai Dallmeier
Flaviviruses such as the dengue (DENV) and the Zika virus (ZIKV) are important human pathogens causing around 100 million symptomatic infections each year. During infection, small subgenomic flavivirus RNAs (sfRNAs) are formed inside the infected host cell as a result of incomplete degradation of the viral RNA genome by cellular exoribonuclease XRN1. Although the full extent of sfRNA functions is to be revealed, these non-coding RNAs are key virulence factors and their detrimental effects on multiple cellular processes seem to consistently involve molecular interactions with RNA-binding proteins (RBPs). Discovery of such sfRNA-binding host-factors has followed established biochemical pull-down approaches skewed towards highly abundant proteins hampering proteome-wide coverage. Yeast three-hybrid (Y3H) systems represent an attractive alternative approach. To facilitate proteome-wide screens for RBP, we revisited and improved existing RNA-Y3H methodology by (1) implementing full-length ORF libraries in combination with (2) efficient yeast mating to increase screening depth and sensitivity, and (3) stringent negative controls to eliminate over-representation of non-specific RNA-binders. These improvements were validated employing the well-characterized interaction between DDX6 (DEAD-box helicase 6) and sfRNA of DENV as paradigm. Our advanced Y3H system was used to screen for human proteins binding to DENV and ZIKV sfRNA, resulting in a list of 69 putative sfRNA-binders, including several previously reported as well as numerous novel RBP host factors. Our methodology requiring no sophisticated infrastructure or analytic pipeline may be employed for the discovery of meaningful RNA–protein interactions at large scale in other fields.

13 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
VLViktor Lemmens
Viktor Lemmens
LKLara Kelchtermans
Lara Kelchtermans
SDSarah Debaveye
Sarah Debaveye
WCWinston Chiu
Winston Chiu
TVThomas Vercruysse
Thomas Vercruysse
KDKai Dallmeier
Kai Dallmeier
Ebola virus (EBOV) and related filoviruses such as Sudan virus (SUDV) threaten global public health. Effective filovirus vaccines are available only for EBOV, yet restricted to emergency use considering a high reactogenicity and demanding logistics. Here we present YF-EBO, a live YF17D-vectored dual-target vaccine candidate expressing EBOV-glycoprotein (GP) as protective antigen. Safety of YF-EBO in mice was further improved over that of parental YF17D vaccine. A single dose of YF-EBO was sufficient to induce high levels of EBOV-GP specific antibodies and cellular immune responses, that protected against lethal infection using EBOV-GP-pseudotyped recombinant vesicular stomatitis virus (rVSV-EBOV) in interferon-deficient ( Ifnar -/- ) mice as surrogate challenge model. Concomitantly induced yellow fever virus (YFV)-specific immunity protected Ifnar -/- mice against intracranial YFV challenge. YF-EBO could thus help to simultaneously combat both EBOV and YFV epidemics. Finally, we demonstrate how to target other highly pathogenic filoviruses such as SUDV at the root of a current outbreak in Uganda.